Damora Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

DMRA$23.70+8.4%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Damora Therapeutics, Inc.
Date: August 10, 2026	By:	/s/ Jennifer Jarrett
		Jennifer Jarrett
		President, Chief Executive Officer and Director (Principal Executive Officer)
Date: August 10, 2026	By:	/s/ Brian Burkavage
		Brian Burkavage
		SVP, Finance(Principal Financial and Accounting Officer)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.